1. Home
  2. NBN vs DSGN Comparison

NBN vs DSGN Comparison

Compare NBN & DSGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

NBN

Northeast Bank

HOLD

Current Price

$131.78

Market Cap

1.1B

Sector

Finance

ML Signal

HOLD

Logo Design Therapeutics Inc.

DSGN

Design Therapeutics Inc.

HOLD

Current Price

$15.02

Market Cap

860.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NBN
DSGN
Founded
1872
2017
Country
United States
United States
Employees
234
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.1B
860.7M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
NBN
DSGN
Price
$131.78
$15.02
Analyst Decision
Buy
Strong Buy
Analyst Count
2
4
Target Price
$130.50
$15.25
AVG Volume (30 Days)
139.8K
997.7K
Earning Date
04-27-2026
04-28-2026
Dividend Yield
0.03%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$13.77
N/A
Revenue Next Year
$18.72
N/A
P/E Ratio
$11.29
N/A
Revenue Growth
N/A
N/A
52 Week Low
$80.75
$3.76
52 Week High
$142.31
$17.25

Technical Indicators

Market Signals
Indicator
NBN
DSGN
Relative Strength Index (RSI) 54.79 64.80
Support Level $115.49 $9.78
Resistance Level $137.08 $17.10
Average True Range (ATR) 3.63 1.09
MACD -0.30 0.17
Stochastic Oscillator 53.05 78.51

Price Performance

Historical Comparison
NBN
DSGN

About NBN Northeast Bank

Northeast Bank provides banking and financial services to individual and corporate customers in the United States. The firm conducts its loan-related activities through two primary channels: the Community Banking Division, and the Small Business Administration (SBA) National Division. Its loan portfolio comprises residential mortgage loans; multi-family and other commercial real estate loans; commercial and industrial loans, consumer loans, and small business administration loans. The firm also provides telephone banking, online banking, mobile banking, and remote deposit capture services. The revenue of the company is derived principally from interest and dividends from the bank.

About DSGN Design Therapeutics Inc.

Design Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the research and development of GeneTAC molecules, which are a novel class of small-molecule gene targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. Its pipeline includes Friedreich Ataxia, FECD, DM1, and Huntington's Disease. The company operates in one operating and reportable segment focused on utilizing the company's proprietary GeneTAC platform to design and develop therapeutic candidates for inherited diseases driven by nucleotide repeat expansion.

Share on Social Networks: